Edition:
United States

EyeGate Pharmaceuticals Inc (EYEG.OQ)

EYEG.OQ on NASDAQ Stock Exchange Capital Market

0.62USD
18 May 2018
Change (% chg)

$0.03 (+5.58%)
Prev Close
$0.59
Open
$0.55
Day's High
$0.64
Day's Low
$0.52
Volume
270,322
Avg. Vol
199,107
52-wk High
$2.42
52-wk Low
$0.29

Chart for

About

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone... (more)

Overall

Beta: --
Market Cap(Mil.): $10.42
Shares Outstanding(Mil.): 17.66
Dividend: --
Yield (%): --

Financials

  EYEG.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -0.82 -- --
ROI: -306.31 13.08 12.63
ROE: -613.68 14.80 14.50

BRIEF-EyeGate Pharmaceuticals Says On May 15, Board Increased Size To Eight From Seven

* EYEGATE PHARMACEUTICALS INC - ON MAY 15, BOARD INCREASED SIZE OF BOARD FROM SEVEN DIRECTORS TO EIGHT DIRECTORS - SEC FILING Source http://bit.ly/2KuxceA Further company coverage:

May 16 2018

BRIEF-Eyegate Pharmaceuticals Posts Q1 Revenue Of $1.096 Million

* EYEGATE PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

May 11 2018

BRIEF-Armistice Capital LLC Reports 50.8 Pct Stake In Eyegate Pharmaceuticals As Of April 13

* ARMISTICE CAPITAL LLC REPORTS 50.8 PERCENT STAKE IN EYEGATE PHARMACEUTICALS INC AS OF APRIL 13 - SEC FILING

Apr 23 2018

BRIEF-Eyegate Announces $11.25 Million Public Offering

* PRICING OF PUBLIC OFFERING OF 35.2 MILLION SHARES OF COMMON STOCK AND WARRANTS TO PURCHASE 35.2 MILLION SHARES OF COMMON STOCK

Apr 13 2018

BRIEF-EyeGate Issued New Patent For Iontophoretic Contact Lens Technology

* EYEGATE ISSUED NEW PATENT FOR IONTOPHORETIC CONTACT LENS TECHNOLOGY Source text for Eikon: Further company coverage:

Apr 11 2018

BRIEF-Eyegate Receives FDA Feedback On Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel

* EYEGATE RECEIVES FDA FEEDBACK ON INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL

Apr 09 2018

BRIEF-EyeGate Gets Milestone Payment For Confirmatory Study Of Eye Inflammation Treatment

* EYEGATE COMPLETES ENROLLMENT AND RECEIVES MILESTONE PAYMENT FOR CONFIRMATORY PHASE 3 CLINICAL STUDY OF EGP-437 IN ANTERIOR UVEITIS Source text for Eikon: Further company coverage:

Apr 06 2018

BRIEF-Eyegate Pharmaceuticals Files For Potential Mixed Shelf Of Up To $20 Mln

* EYEGATE PHARMACEUTICALS FILES FOR POTENTIAL MIXED SHELF OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2ugghJy) Further company coverage:

Mar 23 2018

BRIEF-Eyegate Pharma Submits Investigational Device Exemption Amendment For Second Pilot Study Of Ocular Bandage Gel

* EYEGATE PHARMA SUBMITS INVESTIGATIONAL DEVICE EXEMPTION AMENDMENT FOR SECOND PILOT STUDY OF OCULAR BANDAGE GEL

Mar 08 2018

BRIEF-Eyegate Announces Top-Line Results For Phase 2B Trial Of EGP-437 In Cataract Surgery

* EYEGATE ANNOUNCES TOP-LINE RESULTS FOR PHASE 2B TRIAL OF EGP-437 IN CATARACT SURGERY

Feb 05 2018

Earnings vs. Estimates